| Early detrimental T-cell effects in experimental cerebral ischemia are neither related to adaptive immunity nor thrombus formation C Kleinschnitz, N Schwab, P Kraft, I Hagedorn, A Dreykluft, T Schwarz, ... Blood, The Journal of the American Society of Hematology 115 (18), 3835-3842, 2010 | 392 | 2010 |
| Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation CC Gross, A Schulte-Mecklenbeck, A Rünzi, T Kuhlmann, ... Proceedings of the National Academy of Sciences 113 (21), E2973-E2982, 2016 | 176 | 2016 |
| l-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients N Schwab, T Schneider-Hohendorf, V Posevitz, J Breuer, K Göbel, ... Neurology 81 (10), 865-871, 2013 | 168 | 2013 |
| CD8+ T-cell clones dominate brain infiltrates in Rasmussen encephalitis and persist in the periphery N Schwab, CG Bien, A Waschbisch, A Becker, GH Vince, K Dornmair, ... Brain 132 (5), 1236-1246, 2009 | 156 | 2009 |
| VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells T Schneider-Hohendorf, J Rossaint, H Mohan, D Böning, J Breuer, ... Journal of Experimental Medicine 211 (9), 1833-1846, 2014 | 145 | 2014 |
| Ultraviolet B light attenuates the systemic immune response in central nervous system autoimmunity J Breuer, N Schwab, T Schneider‐Hohendorf, M Marziniak, H Mohan, ... Annals of neurology 75 (5), 739-758, 2014 | 144 | 2014 |
| Natalizumab-associated PML: challenges with incidence, resulting risk, and risk stratification N Schwab, T Schneider-Hohendorf, N Melzer, G Cutter, H Wiendl Neurology 88 (12), 1197-1205, 2017 | 124 | 2017 |
| Fatal PML associated with efalizumab therapy: insights into integrin αLβ2 in JC virus control N Schwab, JC Ulzheimer, RJ Fox, T Schneider-Hohendorf, BC Kieseier, ... Neurology 78 (7), 458-467, 2012 | 123 | 2012 |
| CD8+ T-cell immunity in chronic inflammatory demyelinating polyradiculoneuropathy T Schneider-Hohendorf, N Schwab, N Üçeyler, K Göbel, C Sommer, ... Neurology 78 (6), 402-408, 2012 | 118 | 2012 |
| Risks and risk management in modern multiple sclerosis immunotherapeutic treatment L Klotz, J Havla, N Schwab, R Hohlfeld, M Barnett, S Reddel, H Wiendl Therapeutic advances in neurological disorders 12, 1756286419836571, 2019 | 115 | 2019 |
| CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome CC Gross, C Meyer, U Bhatia, L Yshii, I Kleffner, J Bauer, AR Tröscher, ... Nature communications 10 (1), 5779, 2019 | 109 | 2019 |
| Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects L Klotz, M Eschborn, M Lindner, M Liebmann, M Herold, C Janoschka, ... Science Translational Medicine 11 (490), eaao5563, 2019 | 109 | 2019 |
| T cell suppression by naturally occurring HLA-G-expressing regulatory CD4+ T cells is IL-10-dependent and reversible YH Huang, AL Zozulya, C Weidenfeller, N Schwab, H Wiendl Journal of leukocyte biology 86 (2), 273-281, 2009 | 108 | 2009 |
| CD8+ T-cell pathogenicity in Rasmussen encephalitis elucidated by large-scale T-cell receptor sequencing T Schneider-Hohendorf, H Mohan, CG Bien, J Breuer, A Becker, D Görlich, ... Nature Communications 7 (1), 11153, 2016 | 103 | 2016 |
| An imbalance of two functionally and phenotypically different subsets of plasmacytoid dendritic cells characterizes the dysfunctional immune regulation in multiple sclerosis N Schwab, AL Zozulya, BC Kieseier, KV Toyka, H Wiendl The Journal of Immunology 184 (9), 5368-5374, 2010 | 90 | 2010 |
| Regulatory T cells exhibit enhanced migratory characteristics, a feature impaired in patients with multiple sclerosis T Schneider‐Hohendorf, MP Stenner, C Weidenfeller, AL Zozulya, ... European journal of immunology 40 (12), 3581-3590, 2010 | 87 | 2010 |
| Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values N Schwab, T Schneider-Hohendorf, B Pignolet, J Breuer, CC Gross, ... Neuroimmunology & Neuroinflammation 3 (1), e195, 2016 | 83 | 2016 |
| Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis N Schwab, T Schneider-Hohendorf, H Wiendl International immunology 27 (1), 47-53, 2015 | 81 | 2015 |
| PML risk stratification using anti-JCV antibody index and L-selectin N Schwab, T Schneider-Hohendorf, B Pignolet, M Spadaro, D Görlich, ... Multiple Sclerosis Journal 22 (8), 1048-1060, 2016 | 78 | 2016 |
| FOXP3+ T regulatory cells in idiopathic inflammatory myopathies A Waschbisch, N Schwab, T Ruck, MP Stenner, H Wiendl Journal of Neuroimmunology 225 (1-2), 137-142, 2010 | 68 | 2010 |
Dr. Tilman Schneider-HohendorfUniversity of Muenster, Neurology在 ukmuenster.de 的电子邮件经过验证
